A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group
C Kawai,
Y Yui,
S Hosoda,
M Nobuyoshi,
S Suzuki,
H Sato,
F Takatsu,
T Motomiya,
K Kanmatsuse,
K Kodama,
Y Yabe,
T Minamino,
S Kimata,
and
M Nakashima
Kyoto University, Japan.
OBJECTIVES: This prospective, randomized, double-blind multicenter trial evaluated the efficacy and safety of a single bolus injection of the novel modified tissue-type plasminogen activator (t-PA) E6010 in the treatment of acute myocardial infarction compared with that of native t-PA. BACKGROUND: E6010 is a novel modified t-PA with a prolonged half-life (t1/2 alpha > or = 23 min) compared with native t-PA (t1/2 alpha = 4 min). E6010 can be administered in patients as a single intravenous bolus injection, and early recanalization can be expected. METHODS: The efficacy of E6010 was compared with that of native t-PA in 199 patients with acute myocardial infarction who were treated within 6 h of onset in a prospective, randomized, double-blind multicenter trial. Patients were given either 0.22 mg/kg body weight of E6010 intravenously over 2 min or native t-PA (tisokinase) 28.8 mg or 14.4 million IU (10% of the total dose over 1 to 2 min, the remainder infused over 60 min). RESULTS: The primary end point was the recanalization rate of the infarct-related coronary artery at 60 min after the start of treatment. Time to reperfusion was shorter in the E6010 group than in the native t-PA group. Thrombolysis in Myocardial Infarction flow grade 2 or 3 recanalization at 15, 30, 45 and 60 min after administration was observed in 37%, 62%, 74% and 79% (95% confidence interval [CI] 70% to 87%) of the E6010-treated patients and in 14%, 32%, 50% and 65% (95% CI 55% to 74%) of native t-PA-treated patients, respectively (p = 0.032 at 60 min). CONCLUSIONS: The present study indicates that, compared with native t-PA, a single bolus injection of E6010 over 2 min produces a higher rate of early recanalization of the infarct-related coronary artery without fatal bleeding complications.
This article has been cited by other articles:
|
|
|
|
 
P. W. Armstrong and D. Collen
Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 2
Circulation,
June 19, 2001;
103(24):
2987 - 2992.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Armstrong and D. Collen
Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 1
Circulation,
June 12, 2001;
103(23):
2862 - 2866.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Eikelboom, S. R. Mehta, J. Pogue, and S. Yusuf
Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials: Intracranial Hemorrhage in Trials of Bolus Thrombolytic Therapy
JAMA,
January 24, 2001;
285(4):
444 - 450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Gibson
Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting
Ann Intern Med,
May 18, 1999;
130(10):
841 - 847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
